Sign in
CompletedPhase 4

Simultaneous mRNA COVID-19 and IIV Vaccination in Pregnancy Study

Key facts

Who runs it
Duke University
Where
Atlanta, Boston, Cincinnati, Durham, and Winston-Salem, United StatesSee the 6 sites
Trial code
Status
Completed
Phase
Phase 4
People taking part
98 people enrolled
Started
12 Sept 2024
Ended
19 Nov 2025
Type of study
Interventional, 2 groups
Treatments tested
  • mRNA COVID-19 vaccine
  • IIV4 (quadrivalent inactivated influenza vaccine)
Record updated
7 October 2026

Who can take part

Age
18 years and older
Sex
Women only
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 41 criteriaShow less

Who can take part

  • Pregnant women ages 18 years or older at enrollment
  • Gestational age < 34 weeks 0 days based on reconciliation of last menstrual period and ultrasound dating. Estimated due date (EDD) and Gestational Age (GA-EDD) will be based on reconciliation of "sure" first day of the last menstrual period (LMP) and earliest dating ultrasound. If the LMP is uncertain, then the earliest dating ultrasound will be used to determine EDD and GA. If the ultrasound derived-EDD is in agreement with sure-LMP derived EDD, then the LMP-derived EDD is used to determine GA. If the ultrasound derived EDD is not in agreement with the LMP-derived EDD, the ultrasound-derived EDD is used to determine GA
  • Intention to receive mRNA COVID-19 vaccine
  • Intention to receive influenza vaccine
  • Willing to provide written informed consent
  • Intention of being available for entire study period and complete all relevant study procedures, including follow-up phone calls and collection of delivery information
  • Ability to speak English, Spanish or Haitian/Creole depending on site*; Duke will enroll English and Spanish speaking individuals; Boston will enroll English, Spanish and Haitian Creole speaking individuals; CCHMC will enroll English speaking individuals; Emory will enroll English speaking individuals; Wake Forest will enroll English and Spanish speaking individuals
  • Receiving or planning to receive prenatal care

Who cannot take part

  • Received oral, intramuscular or intravenous systemic immunosuppressants, or immune-modifying drugs for >14 days in total within 6 months prior to any study vaccine dose (for corticosteroids ≥ 20 mg/day of prednisone equivalent). Note: Topical medications are allowed
  • Prior receipt of influenza vaccine during the respective influenza season in which they are being enrolled
  • Prior receipt of COVID-19 vaccine during the respective influenza season in which they are being enrolled
  • Receipt of any licensed non-live vaccine within 7 days prior to study vaccination or intention of receiving any vaccines during the 7-day post-vaccination periods
  • Receipt of any live vaccine during the current pregnancy
  • Severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine, including egg protein, or after previous dose of any influenza vaccine
  • History of a severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a component of the mRNA COVID-19 vaccine
  • History of Guillain-Barré syndrome within 6 weeks of a prior dose of any influenza vaccine
  • History of a non-severe, immediate (onset less than 4 hours) allergic reaction after administration of a previous dose of mRNA COVID-19 vaccine
  • Documented COVID-19 infection within 6 weeks prior to enrollment confirmed by either medical history or lab testing
  • Receipt of blood or plasma products or immunoglobulin from 3 months before study vaccine administration, or planned receipt through delivery, with an exception of Rho(D) immune globulin
  • Prior enrollment in the study
  • Anyone who is already enrolled or plans to enroll in another clinical trial with an investigational product during the study period.*; *Per protocol, co-enrollment in observational or behavioral intervention studies is permitted at any time. An investigational product may be permitted for therapy of an illness condition that occurs during the study period
  • History of febrile illness (> 100.4°F or 38°C) within the past 72 hours prior to vaccine administration
  • History of Guillain-Barré syndrome within 6 weeks of a prior dose of any influenza vaccine
  • Prior receipt of influenza vaccine during the respective influenza season in which they are being enrolled
  • Severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine, including egg protein, or after previous dose of any influenza vaccine
  • Has an active neoplastic disease (excluding nonmelanoma skin cancer), including those who used anticancer chemotherapy or radiation therapy during the current pregnancy or recently (within 36 months of enrollment into study.)
  • History of a diagnosed non-severe allergy to a component of the mRNA COVID-19 vaccine
  • History of multisystem inflammatory syndrome in children (MIS-C) or multisystem inflammatory syndrome in adults (MIS-A)
  • History of myocarditis or pericarditis within 3 weeks after a dose of any COVID-19 vaccine
  • Bleeding disorder or condition associated with prolonged bleeding that would present as a safety risk per opinion of the investigator
  • Any condition which, in the opinion of the investigators, may pose a health risk to the subject or interfere with the evaluation of the study objectives; Temporary Delay Criteria at Visit 1 and 2
  • Any condition which, in the opinion of the investigators, may pose a temporary health risk to the subject or interfere with the evaluation of the study objectives; Visit 2 Eligibility Criteria Review
  • Any condition which, in the opinion of the investigators, may pose a health risk to the subject or interfere with the evaluation of the study objectives
  • Has immunosuppression because of an underlying illness or medications, such as antirejection/transplant regimens or immunomodulatory agents. Stable HIV disease is permitted per the following parameters:; Confirmed stable HIV disease defined as documented viral load <50 copies/mL and CD4 count >200 within 6 months before enrollment, and on stable antiretroviral therapy for at least 6 months
  • Has known hepatitis B (HBV) or hepatitis C (HCV). Stable HBV or HCV are permitted per the following parameters:; If known HBV: confirmed inactive chronic HBV infection: HBsAg present for ≥6 months and HBeAg negative, anti-HBe positive; serum HBV DNA <2000 IU/mL; persistently normal ALT or AST levels; in those who had liver biopsy, findings that confirm absence of significant necroinflammation; If known HCV: evidence of sustained virological response for ≥12 weeks after treatment or without evidence of HCV RNA viremia (undetectable HCV RNA)
  • Signs or symptoms of active preterm labor, defined as regular uterine contractions with cervical change (dilation/effacement)
  • Known multi-fetal gestation
  • Known fetal congenital anomaly, e.g., genetic abnormality or major congenital malformation based on antenatal ultrasound
  • Intending to deliver at a site un-affiliated with the study team
  • Individuals who are known to be delivering early (<37 weeks)
  • Anyone who is a first-degree relative of any research study personnel or is an employee supervised by study staff

Where in United States

  • Centers for Disease Control and PreventionAtlanta, United States
  • Emory UniversityAtlanta, United States
  • Boston Medical CenterBoston, United States
  • Elizabeth SchlaudeckerCincinnati, United States
  • Duke UniversityDurham, United States
  • Wake Forest UniversityWinston-Salem, United States

About the trial

What the trial wants to find out

This study is a prospective, randomized clinical trial. During this study, pregnant women will be randomly assigned to receive IIV and mRNA COVID-19 vaccine either simultaneously or sequentially (7-14 days apart). All participants will receive an mRNA COVID-19 vaccine at Visit 1 (Day 1).

Read full original descriptionShow less

Solicited local and systemic symptoms of reactogenicity will be assessed on day of visit for Visits 1 and 2 and daily during the 6 days following each visit using either electronic or paper symptoms diaries, depending on study participant preference. Serious adverse events (SAE) and adverse events of special interest (AESI) will be collected throughout the duration of the study.

Pregnant women will be followed through delivery with comprehensive obstetric and infant outcomes obtained from medical record review for 90 days post-delivery.

Maternal serum samples will be collected for antibody titers relevant to Influenza and COVID-19 prior to vaccination, at Day 29 (both groups), as well as Days 36-43 if in sequential group. When feasible, maternal blood at delivery and cord blood serum will be analyzed for serological analyses of placental influenza and COVID-19 antibody transfer (cord blood: maternal antibody ratio) will be determined.

The 2 groups in the trial

  • Simultaneous Vaccination GroupTreatment being tested

    Subjects will receive a dose of mRNA COVID-19 vaccine and IIV at Visit 1.

    Treatment: mRNA COVID-19 vaccine and IIV4 (quadrivalent inactivated influenza vaccine)

  • Sequential Vaccination GroupTreatment being tested

    Subjects will receive a dose of mRNA COVID-19 vaccine at Visit 1 and a dose of IIV at Visit 2.

    Treatment: mRNA COVID-19 vaccine and IIV4 (quadrivalent inactivated influenza vaccine)

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Safety of Simultaneous Versus Sequential Administration of mRNA COVID-19 Vaccine and Inactivated Influenza Vaccine (IIV) in Pregnant Women
Record updated
7 October 2026